Charles River Laboratories Intl. (NYSE: CRL) and Rosetta Genomics (NASDAQ:ROSG) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares Charles River Laboratories Intl. and Rosetta Genomics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Charles River Laboratories Intl. $1.68 billion 2.87 $154.76 million $4.09 24.94
Rosetta Genomics $9.23 million 0.35 -$16.23 million N/A N/A

Charles River Laboratories Intl. has higher revenue and earnings than Rosetta Genomics.

Analyst Ratings

This is a summary of recent recommendations for Charles River Laboratories Intl. and Rosetta Genomics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Charles River Laboratories Intl. 0 6 4 0 2.40
Rosetta Genomics 0 1 0 0 2.00

Charles River Laboratories Intl. presently has a consensus target price of $113.80, suggesting a potential upside of 11.58%. Given Charles River Laboratories Intl.’s stronger consensus rating and higher probable upside, equities analysts plainly believe Charles River Laboratories Intl. is more favorable than Rosetta Genomics.

Insider and Institutional Ownership

97.1% of Charles River Laboratories Intl. shares are owned by institutional investors. Comparatively, 7.5% of Rosetta Genomics shares are owned by institutional investors. 2.2% of Charles River Laboratories Intl. shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares Charles River Laboratories Intl. and Rosetta Genomics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Charles River Laboratories Intl. 10.72% 26.58% 8.92%
Rosetta Genomics N/A N/A N/A

Volatility and Risk

Charles River Laboratories Intl. has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Rosetta Genomics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.


Charles River Laboratories Intl. beats Rosetta Genomics on 12 of the 12 factors compared between the two stocks.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company’s clients’ manufacturing activities.

Rosetta Genomics Company Profile

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with's FREE daily email newsletter.